In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Neuro-focused start-up Biohaven nets $180mm in oversubscribed IPO on NYSE

19 Jul 2017

Executive Summary

Orphan neurologic disease start-up Biohaven Pharmaceuticals Holding Co. Ltd. netted $180mm in its initial public offering on the New York Stock Exchange of 11.4mm shares (including the overallotment) at $17, above its anticipated range of $14-16 for 8.3mm shares.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Therapeutic Drug Monitoring
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By